Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review
暂无分享,去创建一个
Sarah R Hoffman | C. Poole | Jennifer S. Smith | C. Willame | A. Lockhart | Sarah R. Hoffman | L. D. Dal Santo | Meagan E. Davis | Tam T. Le | A. Sanusi | Dana A McKinney | M. Brown | Meagan Brown | Meagan Brown | Leila Dal Santo
[1] P. Hillemanns,et al. HPV testing in the context of post-treatment follow up (test of cure). , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[2] L. Mariani,et al. HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions , 2016, Journal of Cancer.
[3] Zhaoning Duan,et al. Analysis of Residual/Recurrent Disease and Its Risk Factors after Loop Electrosurgical Excision Procedure for High-Grade Cervical Intraepithelial Neoplasia , 2015, Gynecologic and Obstetric Investigation.
[4] L. Mariani,et al. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma , 2015, Ecancermedicalscience.
[5] A. Lopes,et al. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test. , 2015, The Cochrane database of systematic reviews.
[6] C. Togrul,et al. Risk factors for human papillomavirus persistence among women undergoing cold‐knife conization for treatment of high‐grade cervical intraepithelial neoplasia , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[7] Jennifer S. Smith,et al. The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. , 2014, Gynecologic oncology.
[8] M. Hudgens,et al. Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta‐analysis , 2013, International journal of cancer.
[9] Robert P Berkowitz,et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.
[10] A. Ryu,et al. Early human papillomavirus testing predicts residual/recurrent disease after LEEP , 2012, Journal of gynecologic oncology.
[11] M. Sherman,et al. Long‐term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment , 2012, International journal of cancer.
[12] A. Fiander,et al. Human Papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[13] W. Silny,et al. Evaluation of HPV DNA HR assay in females as a marker of recurrent disease following treatment of cervical intraepithelial neoplasia. , 2011, Ginekologia polska.
[14] J. Heymans,et al. Type‐specific HPV geno‐typing improves detection of recurrent high‐grade cervical neoplasia after conisation , 2011, International journal of cancer.
[15] P. Bistoletti. Clearance of human papillomavirus in women treated for cervical dysplasia. , 2011, Obstetrics and gynecology.
[16] N. Dogan,et al. The role of HPV DNA testing in the follow-up of cervical intraepithelial neoplasia after loop electrosurgical excision procedure , 2011, Archives of Gynecology and Obstetrics.
[17] J. Nam,et al. Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. , 2010, American journal of obstetrics and gynecology.
[18] J. Thinkhamrop,et al. Cryotherapy for HPV clearance in women with biopsy‐confirmed cervical low‐grade squamous intraepithelial lesions , 2010, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[19] P. Hillemanns,et al. The significance of HPV in the follow-up period after treatment for CIN. , 2010, European journal of gynaecological oncology.
[20] N. Surico,et al. Role of HPV testing in the follow-up of women treated for cervical dysplasia , 2010, Archives of Gynecology and Obstetrics.
[21] I. Bezircioğlu,et al. Residual and recurrent disease rates following LEEP treatment in high-grade cervical intraepithelial lesions , 2010, Archives of Gynecology and Obstetrics.
[22] B. Johansson,et al. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. , 2009, American journal of obstetrics and gynecology.
[23] D. Bae,et al. Factors associated with HPV persistence after conization in patients with negative margins. , 2009, Journal of gynecologic oncology.
[24] C. Meijer,et al. Post‐treatment CIN: Randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease , 2009, International journal of cancer.
[25] M. Temmerman,et al. Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia , 2009, Cytopathology : official journal of the British Society for Clinical Cytology.
[26] C. Poole,et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. , 2008, American journal of epidemiology.
[27] G. Scarselli,et al. PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia. , 2008, Gynecologic oncology.
[28] S. Dong,et al. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. , 2008, Gynecologic oncology.
[29] S. Vansteelandt,et al. Natural history and clearance of HPV after treatment of precancerous cervical lesions , 2008, Histopathology.
[30] M. Fambrini,et al. Prognostic significance of high-risk HPV persistence after laser CO2 conization for high-grade CIN: a prospective clinical study. , 2008, European journal of gynaecological oncology.
[31] S. Namkoong,et al. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure , 2007, International Journal of Gynecologic Cancer.
[32] C. Wheeler,et al. Viral Determinants of Human Papillomavirus Persistence following Loop Electrical Excision Procedure Treatment for Cervical Intraepithelial Neoplasia Grade 2 or 3 , 2007, Cancer Epidemiology Biomarkers & Prevention.
[33] E. Campo,et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. , 2006, Gynecologic oncology.
[34] T. Kucera,et al. Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies , 2006, European Journal of Clinical Microbiology and Infectious Diseases.
[35] C. Wheeler,et al. Human Papillomavirus Testing Following Loop Electrosurgical Excision Procedure Identifies Women at Risk for Posttreatment Cervical Intraepithelial Neoplasia Grade 2 or 3 Disease , 2006, Cancer Epidemiology Biomarkers & Prevention.
[36] L. Mariani,et al. Relationship of Up-Regulation of 67-kd Laminin Receptor to Grade of Cervical Intraepithelial Neoplasia and to High-Risk HPV Types and Prognosis in Cervical Cancer , 2006, Acta Cytologica.
[37] M. Poljak,et al. Efficiency of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions. , 2006, European journal of gynaecological oncology.
[38] N. Brink,et al. The impact of high risk human papillomavirus testing in an inner London colposcopy clinic , 2005, Journal of medical virology.
[39] M. Spitzer,et al. The Role Treatment for Cervical Intraepithelial Neoplasia Plays in the Disappearance of Human Papilloma Virus , 2005, Journal of lower genital tract disease.
[40] L. Sarian,et al. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[41] R. Rosales,et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. , 2004, Human gene therapy.
[42] K. Ohama,et al. Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III - A prospective study. , 2004, International journal of molecular medicine.
[43] S. Yamaguchi,et al. Eradication and reinfection of human papillomavirus after photodynamic therapy for cervical intraepithelial neoplasia , 2003, International Journal of Clinical Oncology.
[44] D. Vinatier,et al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. , 2003, Gynecologic oncology.
[45] A. Kubin,et al. Cold-knife conization versus photodynamic therapy with topical 5-aminolevulinic acid (5-ALA) in cervical intraepithelial neoplasia (CIN) II with associated human papillomavirus infection: a comparison of preliminary results. , 2003, Anticancer research.
[46] Eileen M. Burd,et al. Human Papillomavirus and Cervical Cancer , 1988, The Lancet.
[47] W. Quint,et al. The role of genotype‐specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia , 2002, International journal of cancer.
[48] O. Kimberger,et al. Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis. , 2002, Anticancer research.
[49] J. Dillner,et al. Rate of Human Papillomavirus Clearance After Treatment of Cervical Intraepithelial Neoplasia , 2002, Obstetrics and gynecology.
[50] L. Smart,et al. Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia , 2002, BJOG : an international journal of obstetrics and gynaecology.
[51] S. Hsueh,et al. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. , 2001, American journal of obstetrics and gynecology.
[52] C. Meijer,et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia , 2001, British Journal of Cancer.
[53] B. Mol,et al. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. , 1999, Gynecologic oncology.
[54] A. Teyssié,et al. Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision. , 1998, Infectious diseases in obstetrics and gynecology.
[55] B. Mol,et al. Clearance of Cervical Human Papillomavirus Infection by Treatment for Cervical Dysplasia , 1997, Sexually transmitted diseases.
[56] B. Mol,et al. Human papillomavirus DNA after treatment of cervical dysplasia: Low prevalence in normal cytologic smears , 1996, Cancer.
[57] J. Dillner,et al. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. , 1996, American journal of obstetrics and gynecology.
[58] V. Moreno,et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .
[59] V. Moreno,et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.
[60] E. Piccione,et al. Efficacy of CO2 laser surgery in treating squamous intraepithelial lesions. An analysis of clinical and virologic results. , 1994, The Journal of reproductive medicine.